Compared with low plasma versican, the risk of NSCLC with high plasma versican was 4.741 (95%CI 2.312–9.725, P < 0.001), and the adjusted OR was 1.430 (95%CI 0.567–3.606, P > 0.05); Similarly, compared with low plasma exosomal versican, the risk of NSCLC with high plasma exosomal versican was 6.271 (95%CI 2.966–13.257, P < 0.001), and the adjusted OR was 3.704 (95%CI 1.561–8.790, P = 0.003) (Fig. 8A and B ). This evidence concerns the gene VCAN and non-small cell lung carcinoma.